Key result
Higher monocyte to HDL cholesterol ratio (MHR) is an independent predictor of concomitant cardiovascular disease in Chinese Han patients with obstructive sleep apnea (OR 1.190, P<0.001).
Why the study?
Monocyte to high-density lipoprotein cholesterol ratio (MHR) is a novel inflammatory biomarker of CVD, but has received little attention in obstructive sleep apnea (OSA) studies.
Does the monocyte to HDL cholesterol ratio (MHR) predict concomitant cardiovascular disease in Chinese Han patients with obstructive sleep apnea?
Cross-Sectional (n=657)
Does the monocyte to HDL cholesterol ratio (MHR) predict concomitant cardiovascular disease in Chinese Han patients with obstructive sleep apnea?
Odds Ratio: 1.19
p-value: p=<0.001
MHR is a promising and easily available biomarker for predicting concomitant cardiovascular disease in patients with obstructive sleep apnea.
MHR may support risk stratification in OSA; leaves open prospective validation before clinical adoption.
Background: Obstructive sleep apnea (OSA) is an independent risk factor for cardiovascular disease (CVD), which is attributed to chronic intermittent hypoxia (CIH) induced inflammation. As a new inflammatory biomarker of CVD, monocyte to high-density lipoprotein cholesterol ratio (MHR) has received little attention in OSA studies to date. Therefore, we aimed to investigate the correlation between MHR and concomitant CVD in Chinese Han patients with OSA. Methods: A total of 657 Chinese Han subjects (169 controls, 145 mild, 94 moderate, and 249 severe OSA) of both genders were enrolled in this cross-sectional study, with an average BMI of 32.35±6.56 kg/m2. The relationship between MHR and concomitant CVD in OSA patients was analyzed. Results: The level of MHR was correlated positively with apnea-hypopnea index (AHI), while negatively with lowest SpO2 (P<0.01). Moreover, the MHR values were higher in OSA patients with CVD than those without CVD (17.64±7.16 vs. 12.73±5.06, P<0.001). Logistic regression analysis demonstrated that MHR is an independent predictor of CVD (OR =1.190, P<0.001). The ROC analysis indicated that the best cut-off value of MHR for predicting CVD in OSA patients was 15.364 (sensitivity 65.0%, specificity 74.4%), while its cutoff value for identifying CVD in severe OSA patients was 15.362 (sensitivity 67.3%, specificity 80.1%). Conclusions: MHR is strongly correlated with the severity of OSA and the occurrence of CVD in OSA patients. As an easy and available test, MHR is expected to be a promising biomarker candidate in predicting CVD in Chinese Han patients with OSA.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) conducted a cross-sectional in Obstructive sleep apnea (n=657). Monocyte to high-density lipoprotein cholesterol ratio (MHR) vs. Lower MHR was evaluated on Concomitant cardiovascular disease (CVD) (OR 1.190, p=<0.001). Higher monocyte to HDL cholesterol ratio (MHR) is an independent predictor of concomitant cardiovascular disease in Chinese Han patients with obstructive sleep apnea (OR 1.190, P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: